It is our firm belief that better outcomes are possible for patients with primary genetic immunodeficiencies and cancer. We strive everyday in our pursuit of new, innovative medicines that are designed to restore healthy immunity to treat disease.
Based upon the emerging science of immune regulation, our founders realized the potential of targeting CXCR4 as a validated pathway to stimulate healthy immunity in diseases.
X4 is advancing clinical studies with our pipeline of best-in-class, oral small molecule CXCR4-targeted medicines to treat rare primary immunodeficiency diseases and cancer.
November 06, 2018
X4 Pharmaceuticals Presents Clinical Data Demonstrating...
November 05, 2018
X4 Pharmaceuticals Appoints Gary J. Bridger, PhD, to Board...